NCT Number: NCT00026611
A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults
The purpose of this study is to see how many people respond to a smallpox vaccine when a sore forms where the shot was given.
The world was declared free of smallpox in 1980. General routine vaccinations for smallpox were stopped in the U.S. in 1971. In 1976, the recommendation for routine vaccination of healthcare workers was also discontinued. The only people who presently receive this vaccine are people who work with vaccinia virus or monkeypox virus. Because the world was considered free of smallpox infections, this vaccine was no longer produced; there is a limited supply available in the United States.
Because of the limited amount of Dryvax vaccine (vaccinia virus) against smallpox, this study will look at the ability to dilute the vaccine making more doses available in the event of a smallpox outbreak. The study seeks to characterize a strategy of vaccination against smallpox with various doses of Dryvax, followed by revaccination with the same dose, if required, in volunteers 18-32 years of age with a negative history of smallpox vaccination.
Looking for future studies?
Notify MeKey information
Age range
18 year–32 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
University of Maryland, Baltimore, Maryland, United States
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients may be eligible for this study if they:
- Are between 18 and 32 years of age.
- Give written informed consent.
- Are available for follow-up for 2.5 months.
- Have an acceptable medical history by screening evaluation and brief clinical assessment.
- Are HIV-negative.
- Agree to use acceptable contraception and to not get pregnant during the study.
Exclusion criteria
Patients may not be eligible for this study if they:
- Have a suppressed immune system.
- Have participated in an HIV vaccine trial.
- Have liver disease, diabetes, or kidney problems.
- Have malignant skin cancer.
- Have autoimmune disease.
- Have used medication that suppresses the immune system.
- Have had psychiatric or medical problems or have job responsibilites that will keep them from participating in the study.
- Use illegal intravenous drugs.
- Have received any live vaccines within 60 days of study start.
- Have used experimental therapies within 30 days before study start.
- Have been vaccinated with certain experimental vaccines.
- Have a vaccination scar but have no record of having a vaccine.
- Have received a smallpox vaccine.
- Have taken blood products or immunoglobulin in the past 6 months.
- Have a fever on the day of vaccination.
- Have certain skin disorders, including eczema, exfoliative skin, lacerations that require stitches or burns larger than 2 x 2 cm.
- Live with, have sexual contact with, or work with anyone who is pregnant, less than a year old, has eczema, has certain skin disorders, has a disease or takes medication that suppresses the immune system.
- Have a condition that, in the opinion of the investigator, might interfere with the study.
- Are allergic to any parts of the vaccine.
- Are allergic to thimerosal, immunoglobulins, cidofovir, or probenecid.
- Are pregnant or breast feeding.
Treatment and study plan
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
Registry information
Official study title
A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults
Important dates
- Primary completion
- 2001
- Study completion
- 2001
- First posted
- Nov 13, 2001
- Registry last updated
- Aug 27, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
NCT04971109
DNA Virus Infections, Infections
Miami, Florida, United States
View Trial DetailsSafety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
NCT04392739
DNA Virus Infections, Infections
Austin, Texas, United States
View Trial DetailsDrug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
NCT04485039
DNA Virus Infections, Infections
Austin, Texas, United States
View Trial DetailsA Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
NCT02474589
DNA Virus Infections, Infections
Mobile, Alabama, United States
View Trial Details